ºÃÎĵµ - רҵÎÄÊéд×÷·¶ÎÄ·þÎñ×ÊÁÏ·ÖÏíÍøÕ¾

LYVE-1ÓëѪ¹ÜÄÚƤÉú³¤Òò×Ó-CÔÚºíÁÛ״ϸ°û°©Öеıí´ïºÍÒâÒå

ÓÉ ÌìÏ ·ÖÏí ʱ¼ä£º ¼ÓÈëÊÕ²Ø ÎÒҪͶ¸å µãÔÞ

LYVE-1ÓëѪ¹ÜÄÚƤÉú³¤Òò×Ó-CÔÚºíÁÛ״ϸ°û°©Öеıí´ï

ºÍÒâÒå

ÕÅ´ºÃ÷;Íõ±óÈ«;»Ê¸¦»Ô;ÎÂÊ÷ÐÅ;Õź£Àû

¡¾ÆÚ¿¯Ãû³Æ¡¿¡¶Ö×ÁöÑо¿ÓëÁÙ´²¡· ¡¾Äê(¾í),ÆÚ¡¿2009(021)002

¡¾ÕªÒª¡¿Ä¿µÄ ͨ¹ý²â¶¨ºíÁÛ״ϸ°û°©×éÖ¯ÄÚLYVE-1ºÍѪ¹ÜÄÚƤÉú³¤Òò×Ó-C(VEGF-C)µÄ±í´ïÇé¿ö,ΪºíÁÛ״ϸ°û°©×ªÒƺÍÔ¤ºóµÄÅж¨ÒÔ¼°ÖÎÁÆÌṩһ¶¨µÄÀíÂÛÒÀ¾Ý.·½·¨ ͨ¹ýÃâÒß²¡Àíѧ·½·¨¼ì²âLYVE-1µÄ±í´ï²¢¼ÆÊýºíÁÛ״ϸ°û°©×éÖ¯ÖÐÁܰ͹ÜÃܶÈ(LVD),RT-PCR·¨¼ì²âºíÁÛ״ϸ°û°©ÖÐVEGF-CµÄ±í´ï,ʹÓÃͳ¼Æѧ·½·¨¶ÔLVDºÍVEGF-C±í´ï½øÐзÖÎö.½á¹û ºí°©×éÖ¯ÄÚ´æÔÚLYVE-1(+)µÄ¹ÜÇ»Ñù½á¹¹,LYVE-1ÔÚºí°©×éÖ¯ºÍ°©ÅÔÕý³£×éÖ¯Ö®¼ä±í´ï²îÒìÓÐͳ¼ÆѧÒâÒå(P<0.05),ºí°©×éÖ¯ÖÐVEGF-C mRNAµÄƽ¾ùˮƽÓëÕý³£×éÖ¯Ö®¼ä²îÒìÓÐͳ¼ÆѧÒâÒå(P<0.05),Áö×éÖ¯±ÈÕý³£×éÖ¯¸ß4¡«5±¶,¶øÇÒºí°©×éÖ¯ÄÚVEGF-C±í´ïÓëLVDÖ®¼ä´æÔÚÏà¹ØÐÔ.½áÂÛ ºíÁÛ״ϸ°û°©Áö×éÖ¯ÖдæÔÚÁܰ͹Ü;VEGF-C mRNAÔÚºíÁÛ״ϸ°û°©×éÖ¯Öеıí´ïÒª±ÈÕý³£¶ÔÕÕ×éÖ¯¸ß,ÇÒVEGF-C mRNAµÄ¸ß±í´ï¿ÉÄÜ»áͨ¹ý´Ù½øÁöÄÚÁܰ͹ܵÄÔöÉúÀ´´Ù½øºí°©µÄÁܰͽáתÒÆ.%Objective To elucidate the relationship between LYVE-1 and VEGF-C and their expression in laryngeal squamous cell carcinoma(LSCC),and provide theoretic evidence for the judgement of metastasis and prognosis of LSCC,also for the treatment.Methods An immunohistocbemical analysis was performed to 50 specimens of LSCC with lymphatic endothelial marker LYVE-1.Quantitation of lymphangiogenesis growth factor VEGF-

LYVE-1ÓëѪ¹ÜÄÚƤÉú³¤Òò×Ó-CÔÚºíÁÛ״ϸ°û°©Öеıí´ïºÍÒâÒå

LYVE-1ÓëѪ¹ÜÄÚƤÉú³¤Òò×Ó-CÔÚºíÁÛ״ϸ°û°©Öеıí´ïºÍÒâÒåÕÅ´ºÃ÷;Íõ±óÈ«;»Ê¸¦»Ô;ÎÂÊ÷ÐÅ;Õź£Àû¡¾ÆÚ¿¯Ãû³Æ¡¿¡¶Ö×ÁöÑо¿ÓëÁÙ´²¡·¡¾Äê(¾í),ÆÚ¡¿2009(021)002¡¾ÕªÒª¡¿Ä¿µÄͨ¹ý²â¶¨ºíÁÛ״ϸ°û°©×éÖ¯ÄÚLYVE-1ºÍѪ¹ÜÄÚƤÉú³¤Òò×Ó-C(VEGF-C)µÄ±í´ïÇé¿ö,ΪºíÁÛ״ϸ°û°©×ªÒƺÍÔ¤ºóµÄÅж¨ÒÔ¼°ÖÎÁÆÌṩһ
ÍƼö¶È£º
µã»÷ÏÂÔØÎĵµÎĵµÎªdoc¸ñʽ
8dadw9rg6v3z01x0bvw21wxgu8k8be00nge
ÁìÈ¡¸£Àû

΢ÐÅɨÂëÁìÈ¡¸£Àû

΢ÐÅɨÂë·ÖÏí